# EDGAR Filing Document

**Accession Number:** 0001816307
**File Stem:** 0001104659-25-079589
**Filing Date:** 2025-8
**Character Count:** 29867
**Document Hash:** e3be436466725bc9b9ddbeb950d5e046
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-079589.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001104659-25-079589

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250818

**EFFECTIVENESS DATE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SILVERARC CAPITAL MANAGEMENT, LLC
- **CENTRAL INDEX KEY:** 0001816307

**ORGANIZATION NAME:**
- **EIN:** 834542901
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-21010
- **FILM NUMBER:** 251226459

**BUSINESS ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 620
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617.284.6952

**MAIL ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 620
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001816307

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** SILVERARC CAPITAL MANAGEMENT, LLC

**Address:** 20 Park Plaza, Boston, MA 02116

**Telephone number:** 617-250-8431

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-21010

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                             | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                            | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Avadel Pharmaceuticals Plc                 | G29687103 | 07/30/2024     | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 217230           |                0 | FOR         |                         217230           | FOR                         |  |
| UroGen Pharma Ltd.                         | M96088105 | 08/06/2024     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES | 816853           |                0 | FOR         |                         816853           | FOR                         |  |
| Wave Life Sciences Ltd.                    | Y95308105 | 08/06/2024     | To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES | 385471           |                0 | FOR         |                         385471           | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.               | 76243J105 | 09/18/2024     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 107921           |                0 | FOR         |                         107921           | FOR                         |  |
| Molecular Templates, Inc.                  | 608550208 | 09/27/2024     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 534238           |                0 | FOR         |                         534238           | FOR                         |  |
| KalVista Pharmaceuticals, Inc.             | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 380129           |                0 | FOR         |                         380129           | FOR                         |  |
| Verona Pharma Plc                          | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 351081           |                0 | AGAINST     |                         351081           | AGAINST                     |  |
| Gilead Sciences, Inc.                      | 375558103 | 05/07/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  60950           |                0 | FOR         |                          60950           | FOR                         |  |
| Cytokinetics, Incorporated                 | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  16086           |                0 | FOR         |                          16086           | FOR                         |  |
| Syndax Pharmaceuticals, Inc.               | 87164F105 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 755304           |                0 | FOR         |                         755304           | FOR                         |  |
| Delcath Systems, Inc.                      | 24661P807 | 05/15/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement ("Proxy Statement").                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES | 157815           |                0 | FOR         |                         157815           | FOR                         |  |
| Insmed Incorporated                        | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 204490           |                0 | FOR         |                         204490           | FOR                         |  |
| Travere Therapeutics, Inc.                 | 89422G107 | 05/15/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES | 267032           |                0 | FOR         |                         267032           | FOR                         |  |
| Merus N.V.                                 | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 476423           |                0 | FOR         |                         476423           | FOR                         |  |
| Dianthus Therapeutics, Inc.                | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 134003           |                0 | AGAINST     |                         134003           | AGAINST                     |  |
| 89bio, Inc.                                | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      1.1776e+06  |                0 | FOR         |                              1.1776e+06  | FOR                         |  |
| TELA Bio, Inc.                             | 872381108 | 05/28/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      2.08566e+06 |                0 | FOR         |                              2.08566e+06 | FOR                         |  |
| TELA Bio, Inc.                             | 872381108 | 05/28/2025     | To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      2.08566e+06 |                0 | ONE YEAR    |                              2.08566e+06 | FOR                         |  |
| Kodiak Sciences Inc.                       | 50015M109 | 06/02/2025     | Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 292815           |                0 | FOR         |                         292815           | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 150183           |                0 | FOR         |                         150183           | FOR                         |  |
| Oruka Therapeutics, Inc.                   | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES | 150183           |                0 | ONE YEAR    |                         150183           | FOR                         |  |
| Akero Therapeutics, Inc.                   | 00973Y108 | 06/03/2025     | To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 409776           |                0 | FOR         |                         409776           | FOR                         |  |
| Cerus Corporation                          | 157085101 | 06/03/2025     | The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.89582e+06 |                0 | FOR         |                              1.89582e+06 | FOR                         |  |
| Kiniksa Pharmaceuticals International, plc | G52694109 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  65946           |                0 | FOR         |                          65946           | FOR                         |  |
| Xenon Pharmaceuticals Inc.                 | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers;                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |   6595           |                0 | FOR         |                           6595           | FOR                         |  |
| Celldex Therapeutics, Inc.                 | 15117B202 | 06/05/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 131715           |                0 | FOR         |                         131715           | FOR                         |  |
| Kura Oncology, Inc.                        | 50127T109 | 06/05/2025     | Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 463065           |                0 | FOR         |                         463065           | FOR                         |  |
| Avidity Biosciences, Inc.                  | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and                                                                                         | SECTION 14A SAY-ON-PAY VOTES | 178295           |                0 | AGAINST     |                         178295           | AGAINST                     |  |
| Trevi Therapeutics, Inc.                   | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 368600           |                0 | FOR         |                         368600           | FOR                         |  |
| Trevi Therapeutics, Inc.                   | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 368600           |                0 | ONE YEAR    |                         368600           | FOR                         |  |
| uniQure N.V.                               | N90064101 | 06/11/2025     | Approval, on an advisory basis, of the compensation of the named executive officers of the Company.                                                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |  95481           |                0 | FOR         |                          95481           | FOR                         |  |
| Mersana Therapeutics, Inc.                 | 59045L106 | 06/12/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      2.01765e+06 |                0 | FOR         |                              2.01765e+06 | FOR                         |  |
| Vaxcyte, Inc.                              | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 130571           |                0 | AGAINST     |                         130571           | AGAINST                     |  |
| Vaxart, Inc.                               | 92243A200 | 06/13/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 758069           |                0 | AGAINST     |                         758069           | AGAINST                     |  |
| PTC Therapeutics, Inc.                     | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  64564           |                0 | FOR         |                          64564           | FOR                         |  |
| Veracyte, Inc.                             | 92337F107 | 06/17/2025     | The approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in our proxy statement.                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 403383           |                0 | FOR         |                         403383           | FOR                         |  |
| Veracyte, Inc.                             | 92337F107 | 06/17/2025     | The selection, on a non-binding advisory basis, whether future advisory votes on the compensation paid by us to our named executive officers should be held every one, two or three years.                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 403383           |                0 | ONE YEAR    |                         403383           | FOR                         |  |
| Blueprint Medicines Corporation            | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |  30383           |                0 | FOR         |                          30383           | FOR                         |  |
| C4 Therapeutics, Inc.                      | 12529R107 | 06/18/2025     | To cast a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 417569           |                0 | FOR         |                         417569           | FOR                         |  |
| Nuvalent, Inc.                             | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 213057           |                0 | AGAINST     |                         213057           | AGAINST                     |  |
| BridgeBio Pharma, Inc.                     | 10806X102 | 06/20/2025     | To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 163279           |                0 | AGAINST     |                         163279           | AGAINST                     |  |
| Madrigal Pharmaceuticals, Inc.             | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |   6589           |                0 | FOR         |                           6589           | FOR                         |  |
| Madrigal Pharmaceuticals, Inc.             | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |   6589           |                0 | ONE YEAR    |                           6589           | FOR                         |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |  56042           |                0 | FOR         |                          56042           | FOR                         |  |
| Structure Therapeutics Inc.                | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |  56042           |                0 | ONE YEAR    |                          56042           | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.               | 76243J105 | 06/24/2025     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 255564           |                0 | AGAINST     |                         255564           | AGAINST                     |  |
| Gossamer Bio, Inc.                         | 38341P102 | 06/25/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      3.6841e+06  |                0 | FOR         |                              3.6841e+06  | FOR                         |  |
| Praxis Precision Medicines, Inc.           | 74006W207 | 06/26/2025     | To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | SECTION 14A SAY-ON-PAY VOTES |  80793           |                0 | AGAINST     |                          80793           | AGAINST                     |  |

## N-PX: Signature Block

**Reporting Person:** SILVERARC CAPITAL MANAGEMENT, LLC

**By (Signature):** Paul Brauer Jr

**By (Printed Signature):** Paul Brauer Jr

**By (Title):** Chief Compliance Officer

**Date:** 07/24/2025